BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Haddad AF, Young JS, Amara D, Berger MS, Raleigh DR, Aghi MK, Butowski NA. Mouse models of glioblastoma for the evaluation of novel therapeutic strategies. Neurooncol Adv 2021;3:vdab100. [PMID: 34466804 DOI: 10.1093/noajnl/vdab100] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Maddison K, Bowden NA, Graves MC, Tooney PA. Characteristics of vasculogenic mimicry and tumour to endothelial transdifferentiation in human glioblastoma: a systematic review. BMC Cancer 2023;23:185. [PMID: 36823554 DOI: 10.1186/s12885-023-10659-y] [Reference Citation Analysis]
2 Tran TA, Kim YH, Duong TH, Thangaraj J, Chu TH, Jung S, Kim IY, Moon KS, Kim YJ, Lee TK, Lee CW, Yun H, Lee JJ, Lee HJ, Lee KH, Jung TY. Natural killer cell therapy potentially enhances the antitumor effects of bevacizumab plus irinotecan in a glioblastoma mouse model. Front Immunol 2022;13:1009484. [PMID: 36703992 DOI: 10.3389/fimmu.2022.1009484] [Reference Citation Analysis]
3 Frederico SC, Zhang X, Hu B, Kohanbash G. Pre-clinical models for evaluating glioma targeted immunotherapies. Front Immunol 2022;13:1092399. [PMID: 36700223 DOI: 10.3389/fimmu.2022.1092399] [Reference Citation Analysis]
4 Costas-Insua C, Guzmán M. Endocannabinoid signaling in glioma. Glia 2023;71:127-38. [PMID: 35322459 DOI: 10.1002/glia.24173] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Noorani I, Mischel PS, Swanton C. Leveraging extrachromosomal DNA to fine-tune trials of targeted therapy for glioblastoma: opportunities and challenges. Nat Rev Clin Oncol 2022. [PMID: 36131011 DOI: 10.1038/s41571-022-00679-1] [Reference Citation Analysis]
6 Diaz Rosario M, Kaur H, Tasci E, Shankavaram U, Sproull M, Zhuge Y, Camphausen K, Krauze A. The Next Frontier in Health Disparities—A Closer Look at Exploring Sex Differences in Glioma Data and Omics Analysis, from Bench to Bedside and Back. Biomolecules 2022;12:1203. [DOI: 10.3390/biom12091203] [Reference Citation Analysis]
7 Ivanova EL, Costa B, Eisemann T, Lohr S, Boskovic P, Eichwald V, Meckler J, Jugold M, Orian-rousseau V, Peterziel H, Angel P. CD44 expressed by myeloid cells promotes glioma invasion. Front Oncol 2022;12:969787. [DOI: 10.3389/fonc.2022.969787] [Reference Citation Analysis]
8 Panovska D, De Smet F. Functional Precision Oncology: The Next Frontier to Improve Glioblastoma Outcome? IJMS 2022;23:8637. [DOI: 10.3390/ijms23158637] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Yuzhakova D, Kiseleva E, Shirmanova M, Shcheslavskiy V, Sachkova D, Snopova L, Bederina E, Lukina M, Dudenkova V, Yusubalieva G, Belovezhets T, Matvienko D, Baklaushev V. Highly Invasive Fluorescent/Bioluminescent Patient-Derived Orthotopic Model of Glioblastoma in Mice. Front Oncol 2022;12:897839. [DOI: 10.3389/fonc.2022.897839] [Reference Citation Analysis]
10 Pandey N, Anastasiadis P, Carney CP, Kanvinde PP, Woodworth GF, Winkles JA, Kim AJ. Nanotherapeutic treatment of the invasive glioblastoma tumor microenvironment. Adv Drug Deliv Rev 2022;:114415. [PMID: 35787387 DOI: 10.1016/j.addr.2022.114415] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
11 El Kheir W, Marcos B, Virgilio N, Paquette B, Faucheux N, Lauzon M. Drug Delivery Systems in the Development of Novel Strategies for Glioblastoma Treatment. Pharmaceutics 2022;14:1189. [DOI: 10.3390/pharmaceutics14061189] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Bausart M, Vanvarenberg K, Ucakar B, Lopes A, Vandermeulen G, Malfanti A, Préat V. Combination of DNA Vaccine and Immune Checkpoint Blockades Improves the Immune Response in an Orthotopic Unresectable Glioblastoma Model. Pharmaceutics 2022;14:1025. [DOI: 10.3390/pharmaceutics14051025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Candiota AP, Arús C. Establishing Imaging Biomarkers of Host Immune System Efficacy during Glioblastoma Therapy Response: Challenges, Obstacles and Future Perspectives. Metabolites 2022;12:243. [DOI: 10.3390/metabo12030243] [Reference Citation Analysis]
14 Batara DCR, Zhou S, Choi M, Kim S. Glioblastoma organoid technology: an emerging preclinical models for drug discovery. Organoid 2022;2:e7. [DOI: 10.51335/organoid.2022.2.e7] [Reference Citation Analysis]
15 Haddad AF, Young JS, Oh JY, Okada H, Aghi MK. The immunology of low-grade gliomas. Neurosurg Focus 2022;52:E2. [PMID: 35104791 DOI: 10.3171/2021.11.FOCUS21587] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
16 Lombardi F, Augello FR, Artone S, Gugu MK, Cifone MG, Cinque B, Palumbo P. Up-Regulation of Cyclooxygenase-2 (COX-2) Expression by Temozolomide (TMZ) in Human Glioblastoma (GBM) Cell Lines. Int J Mol Sci 2022;23:1545. [PMID: 35163465 DOI: 10.3390/ijms23031545] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Bausart M, Préat V, Malfanti A. Immunotherapy for glioblastoma: the promise of combination strategies. J Exp Clin Cancer Res 2022;41. [DOI: 10.1186/s13046-022-02251-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
18 Avdoshina DV, Kondrashova AS, Belikova MG, Bayurova EO. Murine Models of Chronic Viral Infections and Associated Cancers. Mol Biol 2022;56:649-67. [PMID: 36217336 DOI: 10.1134/S0026893322050028] [Reference Citation Analysis]